Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-b superfamily and signal through a number of membrane receptors. We have previously demonstrated that the loss of expression of BMP receptors (BMPRs) type IA, -IB, and -II (BMP-RIA, -RIB, and -RII) correlates with Gleason score in prostate cancer patients. To evaluate the prognostic value of this observation, we used immunohistochemistry to investigate the expression of BMPRs in association with disease progression in 60 patients. The results demonstrated a significant association between the loss of expression of the three BMPRs and Gleason score and clinical stage. However, only the loss of expression of BMP-RII showed a statistically significant association with 5-year survival rate (Po0.05) and biochemical recurrence-free rate following radical prostatectomy (Po0.005). To elucidate the effect of an abnormal BMP signaling in prostate cancer cells, we transfected dominant-negative BMP-RII (BMP-RIIDN) into the human prostate cancer cell line, PC3M. When a stable clone overexpressing BMP-RIIDN was inoculated subcutaneously into nude mice, the tumor growth rate was approximately 10 times that of control and parental cell line. These observations, taken together, indicate that the loss of BMP-RII expression as measured by immunohistochemistry may be a prognostic marker in prostate cancer patients, and that the loss of BMP-RII function may result in increased tumorigenicity in human prostate cancer cells.
Introduction
Prostate cancer is the most common malignancy and the second leading cause of male caner deaths in the US (Jemal et al., 2003) . At the present time, accepted treatment options include surgery, watchful waiting, radiotherapy, and hormonal ablation. Since each of the available treatments is associated with significant morbidity and/or mortality, controversies remain regarding selection of patients and choice of treatments. To provide patients with a more accurate prediction of the clinical behavior of prostate cancer and to establish criteria for appropriate patient and therapy selection, additional information is necessary.
Bone morphogenetic proteins (BMPs), the largest subgroup within the transforming growth factor-b (TGF-b) superfamily, were originally isolated as factors that induce bone and cartilage formation (Wozney et al., 1988; Sampath et al., 1992) . Later work has demonstrated that normal BMP function is critical during mammalian development, cellular chemotaxis, and cellular differentiation (reviews by Hogan, 1996; Zhao, 2003) . On the basis of sequence homology, BMPs are divided into several subgroups. Investigation of BMP knockout mice suggests that each type of BMP may function independently (reviewed by Zhao, 2003) . However, the specific role or roles for each type of BMP remain unclear.
BMP signal transduction follows the paradigm established by TGF-b signaling. As with TGF-b, BMPs signal through an interaction with a heteromeric complex of membrane receptors -type I and type II (Liu et al., 1995) . Specifically, ligand binding results in crossphosphorylation of type I receptor by type II receptor; type I receptor, in turn, propagates BMP signaling. Currently, three type I receptors (Act-RI, BMP-RIA, and BMP-RIB) and three type II receptors (Act-RII, Act-RIIB, and BMP-RII) have been identified. In vitro experiments have shown that all members of BMPs that belong to the TGF-b superfamily bind to BMP-RII in combination with BMP-RIA or -RIB . In contrast, Act-RII/-RIIB and Act-RI does not bind BMP-4 (ten Dijke et al., 1994) . Therefore, we focused on BMP-RII, -IA, and -IB in the present study. In the prostate, the level of expression of BMP-RIB has been shown to be high (Ide et al., 1997a) and BMP-4 and -7 have been suggested to play important roles during the development of the prostate (Thomas et al., 1998; Lamm et al., 2001) . In addition, BMP-2, -3, -4, and -6 have been detected in normal and malignant prostate tissues (Harris et al., 1994; Autzen et al., 1998) while BMP-2 has been reported to have a bidirectional effect in the prostate cancer cell line, LNCaP (Ide et al., 1997b) . More recently, it has been suggested that the expression of BMP-7 is androgen dependent (Thomas et al., 1998; Masuda et al., 2004) . In prostate cancer tissues, increased levels of expression of BMP-6 and -7 have been correlated with bone metastasis (Hamdy et al., 1997; Autzen et al., 1998; Masuda et al., 2003) while the loss of expression of BMP-2 is associated with prostate cancer progression (Horvath et al., 2004) . Previously, our laboratory has reported an inverse correlation between an abnormal expression of BMPRs and the pathological grade of prostate cancer (Kim et al., 2000) . As a follow-up of our published work, the present study investigated the prognostic value of the expression of BMPRs in 60 prostate cancer patients and the physiological significance of the loss of BMP signaling in prostate cancer cells by overexpressing BMP-RII dominant negative (BMP-RIIDN) in a human prostate cancer cell line, PC3M. Table 1 shows the histopathologic characteristics of the specimens used in this study while Figure 1 demonstrates the representative result of an immunohistochemistry. Previously, we have demonstrated that the expression of BMPRs is localized to the epithelial compartment in normal prostate, and that human prostate cancer tissues frequently have a loss of expression of BMPRs (Kim et al., 2000) . When the status of BMPRs expression was analysed with respect to tumor grade and clinical stage, a statistically significant association was observed between the two parameters and the three BMPRs (Table 2 ). In the 12 cases of well-differentiated cancer (Gleason score 4), the expression of BMP-RIA, -RIB, and -RII was negative in 16.7, 16.7, and 33.3%, respectively. In contrast, the expression of BMP-RIA, -RIB, and -RII was negative in 76.9, 84.6, and 76.9%, respectively, of the 26 cases of poorly differentiated tumors (Gleason 8-10) (Po0.005 for all three BMPRs). To investigate the relationship between the expression of BMPRs and the tumor stage, patients were classified into organ-confined (T1-T2) and nonorgan-confined groups (T3-T4). As with tumor grade, the correlations between tumor stage and the expression status of all three BMPRs were statistically significant (Po0.05 for all three receptors). 
Results

Expression of BMPRs in human prostate cancer tissues
Expression of BMPRs and prognosis in prostate cancer patients
To determine the potential prognostic value of BMPRs expression, we analysed the biochemical recurrence-free rate 5 years after retropubic radical prostatectomy. Recurrence was defined as rising PSA on two measurements, each greater than 0.1 ng/ml. As shown in Figure 2 , only the loss of expression of BMP-RII was associated with a higher rate of recurrence (P ¼ 0.0012). Next, we explored the relationship between the status of BMPRs expression and the probability of survival 5 years after radical prostatectomy (Figure 3) . The results demonstrated that the expression of BMP-RII correlated with the rate of 5-year survival (P ¼ 0.0370).
As with the biochemical recurrence rate, there was no statistically significant association between the probability of survival and the expression of BMP-RIA and -RIB. To determine whether or not the status of expression of BMPRs is an independent prognostic factor in prostate cancer patients, a multivariate Cox (c) BMP-RII. A total of 60 formalin-fixed prostate cancer specimens harvested from patients who underwent radical prostatectomy as the initial treatment were processed for immunohistochemical staining. Biochemical recurrence was defined as increase in PSA on two measurements, each greater than 0.1 ng/ml. In all, 60 formalinfixed prostate cancer specimens harvested from patients who underwent radical prostatectomy as the initial treatment were processed for immunohistochemical staining. All cases were classified into either positive or negative staining for BMPRs. Specimens were classified as positive if 410% of cells had a staining intensity greater than that of negative control slides per high-power field. At least three high-power fields were reviewed for each case. All cases were confirmed with at least two independent staining experiments and reviewed by at least two investigators independently (IYK and DHL). Only the loss of expression of BMP-RII was associated with a decreased recurrence-free rate in prostate cancer patients (P ¼ 0.0012)
proportional hazards regression analysis that included preoperative PSA, pathological stage, and Gleason score was carried out. The results demonstrated that the status of BMPRs expression was not an independent predictor of prognosis in prostate cancer patients (data not shown). However, it is likely that the number of patients analysed in this study is not sufficient to determine the prognostic value of BMPRs expression as an independent factor in prostate cancer patients.
Effect of BMP-6 and expression of its receptors in human prostate cancer cell lines
To elucidate the role of BMP and its receptors in prostate cancer cells, the effect of BMP-6 was investigated in four human prostate cancer cell linesLNCaP, DU145, PC3, and PC3M. BMP-6 was chosen over BMP-2, -4, and -7 in the present investigation because we had observed that BMP-6 was the most potent inhibitor of cellular growth in tissue culture (data not shown). The results demonstrated that all four prostate cancer cell lines were sensitive to BMP-6 in a dose-dependent manner (Figure 4 ). At 100 ng/ml of BMP-6, the cell numbers of the four cell lines ranged from 28.8 to 39.4% of those of the control. Next, the expression status of BMP-RIA, -RIB, and -RII was investigated using Northern blot analysis. As previously reported, there were two and three splice variants for BMP-RIA and -RII, respectively. As expected, all four cell lines expressed the three BMPRs Sensitivity to BMP-6 in human prostate cancer cell lines. Cells were cultured for 4 days in RPMI-1640 supplemented with 1% FBS containing BMP-6 at 0, 10, 100, and 500 ng/ml. The medium was changed at day 2. At the end of the 4-day period, cells were trypsinized with 0.5 ml of 0.05% trypsin and counted using a hemocytometer. All four human prostate cancer cell lines were sensitive to the growth inhibitory effect of BMP-6 BMP-RIIDN-H nor -L cells exhibited any difference in the rate of proliferation when compared with parental and control cell lines (data not shown). However, when these cells were treated with increasing doses of BMP-6, we observed that BMP-RIIDN-H was resistant to the growth-inhibitory effect of BMP-6, whereas BMP-RIIDN-L cells exhibited an intermediate sensitivity to BMP-6 when compared to the parental and BMP-RIIDN-H cells (Figure 6c ).
Effect of BMP-RIIDN on tumorigenic potential in PC3M cells
Next, BMP-RIIDN-H cells were injected subcutaneously into nude mice and tumor volume was followed for 3 weeks. As shown in Figure 7a , there was an approximately 10-fold increase in the weight of tumor in BMP-RIIDN-H when compared with parental and control cells (pcDNA3.1); H&E staining showed no obvious histologic difference (Figure 7b ). After the tumor samples were harvested, immunoblot using the flag antibody confirmed that the tumor xenografts expressed BMP-RIIDN (Figure 7c) . Autopsy of the animals demonstrated no obvious metastases in either control or experimental mice; microscopic examination of H&E-stained liver, lung, and vertebra revealed no micrometastases (data not shown). These results, taken together, suggest that the loss of function of BMP-RII through the overexpression of BMP-RIIDN leads to an increased tumorigenicity in prostate cancer cells.
Discussion
Results of the present study have demonstrated that the loss of expression of BMP-RII is associated with high tumor grade, high pathological stage, increased rate of recurrence, and decreased rate of survival after surgery. Using tissue culture, we have shown that the human prostate cancer cell lines -LNCaP, DU145, PC3, and PC3M -are inhibited by BMP-6 in a dose-dependent manner and that all four cell lines express BMP-RII, -RIA, and -RIB. When the metastatic variant of PC3 cells, PC3M, was transfected with BMP-RIIDN, BMP-6 was no longer able to inhibit cellular proliferation. Moreover, inoculation of these BMP-RIIDN-expressing cells into nude mice led to an increased tumorigenicity. Taken together, these results suggest that the loss of expression of BMP-RII is a potential molecular marker in prostate cancer patients, and that the loss of BMP signaling in prostate cancer cells may lead to an enhanced tumorigenicity and contribute to tumor progression.
Previously, we demonstrated a correlation between Gleason score and BMPRs expression status in prostate cancer cells (Kim et al., 2000) . In the present study, we observed that the loss of expression of BMP-RII, but not BMP-RIA and -RIB, correlated with prognosis in prostate cancer patients; multivariate analysis, however, failed to show that BMPRs are prognostic factors independent of Gleason score and tumor stage. The limited number of patients analysed in this study preclude definitive exploration of this issue. Since both BMP-RI and -RII are required for BMP signaling, the loss of expression of BMP-RI should have the same biological effects as the loss of expression of BMP-RII. Since there are additional type I receptors for BMP signaling (Act-RI and Act-RIB), it is possible that the expression status of these receptors will predict outcome. Alternatively, the possibility exists that in prostate cancer cells, the biological consequence of the loss of BMP-RI expression may not be the same as that of the loss of BMP-RII expression. Indeed, it has recently been demonstrated that the cytoskeletal regulator LIM kinase 1 (LIMK1) interacts specifically with the tail of BMP-RII and signals independent of the Smad pathway (Foletta et al., 2003) .
The four prostate cancer cell lines investigated in this study expressed detectable levels of BMP-RIA, -RIB, and -RII and were inhibited by BMP-6 in a dosedependent manner. We have also observed that BMP-6 inhibits the proliferation of renal cell carcinoma cell lines (Kim et al., 2003) and bladder transitional cell carcinoma cells (unpublished observations) and others Immunoblot analysis. One million cells were inoculated each into five mice per group and tumor volume was followed for 3 weeks. At the end of the 3-week period, all animals were killed and autopsies were performed. There was approximately a 10-fold increase in tumor weight in BMP-RIIDN-H when compared to parental and control cells (pcDNA3.1); H&E staining showed no obvious histologic difference. Immunoblot using flag antibody performed after the tumor samples were harvested confirmed that the tumor xenografts expressed BMP-RIIDN Loss of expression of BMP receptor IY Kim et al have reported that BMPs inhibit the proliferation or induce apoptosis in gastric, lung adenocarcinoma, and myeloma cells (Kawamura et al., 2002; Buckley et al., 2004; Wen et al., 2004) . This observed negative effect of BMP-6 is consistent with the general characteristics of TGF-b superfamily members and supports the notion that BMPs are differentiating factors that regulate homeostasis and prevent abnormal proliferation of prostate epithelial cells. We have observed, as have others (Brubaker et al., 2004) , that BMP-2 and -4 do not significantly inhibit PC3 cells (unpublished observation). Indeed, BMP-6 was chosen in the present study because BMP-6 was able to consistently inhibit the proliferation of the four prostate cancer cell lines -LNCaP, DU145, PC3, and PC3M. This observation is consistent with the results obtained with knockout mice demonstrating that each BMP subtype has distinct functions (reviewed by Zhao, 2003) . Although the precise mechanism for the difference in sensitivity to various members of BMPs in PC3 cells is not clear at the present time, receptor heterogeneity is one potential explanation because there are at least three type I and three type II BMP receptors with varying affinity for each BMP subtype (ten Dijke et al., 1994) . Further investigation is necessary to test this hypothesis.
In agreement with the paradigm of expression of TGF-b and its receptors during carcinogenesis, the present study demonstrated a significant increase in tumorigenic potential in PC3M cells when rendered resistant to the growth-inhibitory effect of BMP-6 by overexpressing BMP-RIIDN. Specifically, tumor weight of clones expressing high levels of BMP-RIIDN was more than 10 times that of the control and parental cell lines 3 weeks after the inoculation. These results suggest that an intact BMP-signaling pathway may comprise a novel tumor suppressor pathway in PC3M cells, and that members of BMP-signal transduction cascade may be tumor suppressor genes. To date, no genetic mutation of BMPRs has been reported in malignant cells, although mutated BMP-RII has been detected in primary pulmonary hypertension (Rudarakanchana et al., 2002) . Using laser capture microscopy, we have also identified multiple BMP-RII mutations in prostate cancer patients (unpublished observations). Currently, we are in the process of characterizing these mutations. Interestingly, the rate of proliferation of BMP-RIIDN-H in tissue culture was not significantly different from that of parental cells when cultured in the standard medium supplemented with either 1% or 10% FBS. Since a dramatic increase in tumor growth was observed in mice, it is likely that the local concentration of BMPs may be significantly higher in vivo.
Since BMPs are abundant in the bone and inhibit cellular proliferation of prostate cancer cells, we expected an increase in the rate of bone metastasis in PC3M cells that are rendered insensitive to BMPs. However, we detected no metastasis in either control or BMP-RIIDN-overexpressing cells. Tumor metastasis is a complex process that involves a close interplay between tumor cells and surrounding microenvironment. It is likely that the genetic alterations necessary for surviving and proliferating at secondary sites are not the same as those required for the vascular/lymphatic invasion from the primary site that leads to the shedding of tumor cells into the circulatory system. Since we inoculated cells subcutaneously, our results suggest that altered BMP signaling is not sufficient for metastatic spread of tumor cells from the primary site. However, the possibility remains that altered BMP signaling may permit prostate cancer cells to survive and proliferate in the bone.
It has been reported that the neutralization of BMP signaling through the overexpression of BMP-RIIDN led to a decreased tumorigenic potential in a breast cancer cell line (Pouliot et al., 2003) . One potential explanation for the observed discrepancy of the effect of BMP-RII between prostate and breast cancer is that the function of BMP may vary among different cell lines and types of malignancies. For example, TGF-b has been shown to have both growth-inhibitory and -promoting effect in different cell lines (Kim et al., 1996; Sintich et al., 1999) . Another interesting possibility is that the effect of BMP may change with tumor progression just as TGF-b suppresses tumor growth in early stage and promotes tumor progression in late stage of carcinogenesis (Derynck et al., 2001 ). Additional work is necessary to test these hypotheses.
Finally, PC3 cells have been reported to express levels of BMP-RIA and -RIB undetectable by immunoblot analysis while BMP-RIA protein was not detected in LNCaP cells (Brubaker et al., 2004) . Although the inconsistency between the present and the aforementioned study is unclear, a potential explanation includes a difference in the experimental protocol used for the immunoblot analysis. Specifically, we used a different primary antibody, loaded higher amounts of protein in each lane (100 vs 30 mg), and routinely incubated all our membranes with the primary antibodies overnight (vs 2 h); the secondary antibody used also was different (1 : 3000 goat-anti-rabbit vs 1 : 50 000 donkey-anti-goat). Alternatively, the culture conditions and the passage number of cells used may be different since it has been reported that the level of expression of BMP-RIB varies with the culture condition in LNCaP cells (Ide et al., 1997b) .
In conclusion, results of the present study demonstrated that the loss of expression of BMP-RII correlates with poor prognosis in prostate cancer patients, and that the human prostate cancer cell lines -PC3, PC3M, LNCaP, and DU145 -express BMP-RII, -RIA, and -RIB and are inhibited by BMP-6. When BMP signaling was abrogated through the overexpression of BMP-RIIDN, tumorigenic potential of the prostate cancer cell line, PC3M, increased.
Materials and methods
Patients
A total of 60 patients with carcinoma of the prostate who underwent radical prostatectomy between 1991 and 1996 were included in the study if 5-year follow-up data were available. Of the 60 patients, 40 were treated at Baylor College of Medicine (Houston, TX, USA) while 20 were treated at Asan Medical Center (Seoul, Korea). In total, 40 of these cases were the subject of our earlier report (Kim et al., 2000) . Radical prostatectomy was the only initial treatment. Table 1 summarizes the Gleason score and pathologic stage.
Tissue specimens
Formalin-fixed and paraffin-embedded tissue specimens of histopathologically diagnosed prostate cancer were obtained from the archives of the Scott Department of Urology, Baylor College of Medicine (Houston, TX, USA) and the Department of Pathology, Asan Medical Center (Seoul, Korea). Sections at 4-mm thickness were made and kept at room temperature until use. One of the sequential sections from each specimen was stained with hematoxylin and eosin (H&E) to assess the histopathological grading according to the Gleason score.
Immunohistochemistry
Immunohistochesmistry was carried out using the Vectastain elite ABC Kit for rabbit IgG (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's protocol. Archival prostate cancer specimens fixed in neutral-buffered formalin were sectioned at a thickness of 4 mm, deparaffinized in xylene and rehydrated in phosphate-buffered saline (PBS). Endogenous peroxidase activity was inactivated by incubation in 0.3% H 2 O 2 for 10 min. Following a preincubation with 2% normal goat serum to block nonspecific sites, the sections were incubated with primary antibodies in a humidified chamber for 18 h at 41C. All three primary antibodies were kindly provided by Dr Kohei Miyazono (The Cancer Institute, Tokyo, Japan). The specificity of the antibodies has been demonstrated previously by our laboratory and others (Yamada et al., 1996; Yonemori et al., 1997; Kim et al., 2000) . All three primary antibodies were used at a concentration of 4 mg/ml. Antigenic binding sites were visualized using a serial incubation with biotinylated goat-anti-rabbit secondary antibody, followed by the avidin-biotin-horseradish peroxidase complex, and diaminobenzidine tetrahydrochloride before counterstaining with Gill's hematoxylin. Negative control sections were processed in an identical manner after substituting a normal rabbit IgG fraction for the primary antibody.
All cases were classified on the basis of either positive or negative staining for BMPRs. Specimens were classified as positive if 410% of cells had a staining intensity greater than that of negative control slides per high-power field. At least three high-power fields were reviewed for each case. All cases were confirmed with at least two independent staining experiments and reviewed by at least two investigators (IYK and DHL) independently.
Cell culture and mitogenic assay
The human prostate cancer cell lines -PC3, PC3M, DU145, and LNCaP -were routinely maintained in RPMI-1640 supplemented with 10% fetal bovine serum (FBS). PC3M is a metastatic variant of PC3 cells that have been thoroughly characterized (Blagosklonny et al., 1995) . All cells used in this study were from the 45th through the 52nd passages. For cell counts, cells were plated at 20 000/well in 24-well culture plates in RPMI-1640 supplemented with 10% FBS and allowed to adhere for 24 h. Then, cultures were washed two times with PBS and cells from previously selected wells were counted to determine the plating efficiency. Cells in the remaining wells were cultured for 4 days in RPMI-1640 supplemented with 1% FBS containing BMP-6 (R&D Systems, Minneapolis, MN, USA) at 0, 10, 100, and 500 ng/ml. The medium was changed at day 2. At the end of the 4-day period, cells were trypsinized with 0.5 ml of 0.05% trypsin and counted using a hemocytometer. All treatments were performed in triplicates.
RNA isolation and Northern blot analysis
Cells were harvested and total RNA was isolated using the TRIzol reagent (Gibco-BRL, Grand Island, NY, USA) according to the manufacturer's protocol. Once isolated, 15 mg of total RNA was separated by electrophoresis in 1% formaldehyde-agarose gel and transferred to a nylon membrane (Zeta-Probe GT membrane, Bio-Rad Laboratories, Hercules, CA, USA). Prehybridization was performed in 50% formamide, 0.12 M Na 2 HPO 4 (pH 7.2), 0.25 M NaCl, 7% wt/vol SDS, and 250 mg/ml heat-denatured salmon sperm DNA for 2 h at 421C. Hybridization was performed overnight at 421C in the prehybridization solution containing probes labeled with 32 P-dCTP using a random oligonucleotide priming kit (Prime It, Stratagene, La Jolla, CA, USA). Complete cDNAs for all three BMPRs were the gift of Dr Kohei Miyazono and were used to label the probes. The membranes were washed sequentially in 2 Â SSC-0.1% SDS for 15 min, 0.5 Â SSC-0.1% SDS for 15 min, and 0.1 Â SSC-0.1% SDS for 30 min. Autoradiography was carried out at À701C.
Immunoblot analysis
Cells were harvested, placed in sample buffer (0.0625 M Trizma base, 2% SDS, and 5% 2-mercaptoethanol), and boiled for 5 min. Electrophoresis was carried out using 100 mg of total protein in each lane. After electrophoresis, protein was transferred to a 0.2-mm nitrocellulose membrane (Bio-Rad). Subsequently, the membrane was blocked with blocking buffer-TBST (5% nonfat dry milk, Tris-buffered saline, and 0.1% Tween) for 1 h and incubated with the appropriate primary antibody at a concentration of 0.4 mg/ml overnight at 41C. As with immunohistochemistry, all three primary antibodies were obtained from Dr Kohei Miyazono. Anti-flag antibody was purchased from Sigma-Aldrich (St Louis, MO, USA). After being washed with TBST, the membrane was incubated in the presence of the goat-anti-rabbit secondary antibody (Bio-Rad) at a dilution of 1 : 3000 for 2 h. Several washings were carried out and immunoreactive bands were visualized by enhanced chemiluminescence (Amersham, Piscataway, NJ, USA).
Transfection assay
For stable transfections, cells were seeded in six-well plates at 100 000/well. After the cells were allowed to adhere, they were transfected using Lipofectin according to the manufacturer's directions (Gibco-BRL). In total, 1 mg of BMP-RIIDN-flag expression vector and 12 ml of Lipofectin were added with 1 ml of the transfection medium (Opti-mem, Gibco-BRL) to each well. Subsequently, stable clones were selected in the presence of G418 at 400 mg/ml. The plasmid containing the sequence for BMP-RIIDN protein tagged with the flag epitope was graciously given by Dr Kohei Miyazono. Briefly, BMP-RIIDN was generated by PCR truncating the receptor 10 amino acids after the transmembrane domain. The fragment was then cloned in-frame into pcDNA3.1 expression vector containing the flag epitope at the carboxyl terminal.
Animal studies
Adult male nude mice were obtained from the National Cancer Institute and housed according to the NIH standards established in the guidelines for the Care and Use of Experimental Animals. One million cells were inoculated each into five mice per group and tumor volume was followed for 3 weeks. Tumor volume was calculated using the following standard formula: l Â s 2 Â 0.52 where l is the longest and s is the shortest diameter. At the end of the 3-week period, all animals were killed and autopsies were performed to examine for any gross evidence of metastasis. In addition, liver, lung, and vertebra were harvested, fixed in formalin, and stained with H & E for microscopic examination.
Statistical analysis
All in vitro assays were performed at least three times while the animal experiment was performed once. All numerical data obtained from tissue culture are expressed as mean7s.e.m. of triplicate observations. Differences of means among different treatments were compared by w 2 . The correlation between BMPRs expression and tumor grade and pathologic stage was also evaluated by w 2 . Survival was calculated on the basis of the date of death due to prostate cancer while the recurrence rate was calculated from the date of surgery to the date of the first documented biochemical recurrence. Biochemical recurrence was defined as rising prostate-specific antigen (PSA) on two measurements, each greater than 0.1 ng/ml. Kaplan-Meier method was used to evaluate the data concerning the survival and the recurrence rate and the statistical significance of the differences was tested with log-rank test. The multivariate survival analysis was performed with the Cox proportional hazards model. All analyses were performed with the SPSS statistical package (SPSS, Inc., Chicago, IL, USA). In this study, a value of Po0.05 was considered statistically significant.
